<a href="https://www.fiercebiotech.com/biotech/bain-backed-beeline-medicines-buzzes-out-stealth-300m-and-5-programs-bms" hreflang="en">Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS</a>
fiercebiotech.com·Apr 14, 2026
Former leaders of SpringWorks Therapeutics have launched a new biotech company, which has gained significant attention after securing $300 million in a Series A funding round.
The formation of a new biotech venture by the former leaders of SpringWorks Therapeutics, backed by a substantial $300 million Series A, signals a strong market confidence and potential for innovative developments in the biotech space. This could be an opportune moment for healthtech investors and stakeholders to monitor this venture for breakthroughs in drug discovery or novel therapeutic approaches.